NeoGenomics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
NeoGenomics, Inc. (NEO) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $7.77 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-04-30.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2024-04-30
- NeoGenomics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2024-03-31 was $7.77M, a 63.39% increase year-over-year.
- NeoGenomics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2023-09-30 was $6.90M, a 71.51% increase year-over-year.
- NeoGenomics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2023-06-30 was $5.45M, a 63.57% increase year-over-year.
- NeoGenomics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2023-03-31 was $4.76M, a 59.87% decline year-over-year.
- NeoGenomics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $24.63M, a 0.16% decline from fiscal 2022.
- NeoGenomics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $24.67M, a 9.86% increase from fiscal 2021.
- NeoGenomics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $22.46M, a 140.53% increase from fiscal 2020.
- NeoGenomics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2020 was $9.34M, a 0.52% decline from fiscal 2019.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2024-03-31 | $7.77M 10-Q · filed 2024-04-30 | |||||
| 2023-12-31 | $24.63M 10-K · filed 2024-02-20 | |||||
| 2023-09-30 | $6.90M 10-Q · filed 2023-11-06 | $12.35M derived: sum of 2 quarters · filed 2023-11-06 | $17.11M derived: sum of 3 quarters · filed 2024-04-30 | |||
| 2023-06-30 | $5.45M 10-Q · filed 2023-11-06 | $10.21M derived: sum of 2 quarters · filed 2024-04-30 | ||||
| 2023-03-31 | $4.76M 10-Q · filed 2024-04-30 | $4.48M 10-Q · filed 2023-05-09 | ||||
| 2022-12-31 | $24.67M 10-K · filed 2024-02-20 | $23.63M 10-K · filed 2023-02-24 | ||||
| 2022-09-30 | $4.02M 10-Q · filed 2023-11-06 | $7.36M derived: sum of 2 quarters · filed 2023-11-06 | $19.21M derived: sum of 3 quarters · filed 2023-11-06 | |||
| 2022-06-30 | $3.33M 10-Q · filed 2023-11-06 | $15.19M derived: sum of 2 quarters · filed 2023-11-06 | ||||
| 2022-03-31 | $11.86M 10-Q · filed 2023-11-06 | |||||
| 2021-12-31 | $22.46M 10-K · filed 2024-02-20 | $21.41M 10-K · filed 2022-02-25 | ||||
| 2021-09-30 | $5.00M 10-Q · filed 2022-11-08 | $9.21M derived: sum of 2 quarters · filed 2022-11-08 | $11.62M derived: sum of 3 quarters · filed 2022-11-08 | |||
| 2021-06-30 | $4.21M 10-Q · filed 2022-11-08 | $6.62M derived: sum of 2 quarters · filed 2022-11-08 | ||||
| 2021-03-31 | $2.41M 10-Q · filed 2022-11-08 | |||||
| 2020-12-31 | $9.34M 10-K · filed 2023-02-24 | |||||
| 2020-09-30 | $2.49M 10-Q · filed 2021-11-04 | $4.92M derived: sum of 2 quarters · filed 2021-11-04 | $6.91M derived: sum of 3 quarters · filed 2021-11-04 | |||
| 2020-06-30 | $2.42M 10-Q · filed 2021-11-04 | $4.42M derived: sum of 2 quarters · filed 2021-11-04 | ||||
| 2020-03-31 | $1.99M 10-Q · filed 2021-11-04 | |||||
| 2019-12-31 | $9.39M 10-K · filed 2022-02-25 | |||||
| 2019-09-30 | $3.13M 10-Q · filed 2020-10-29 | $5.28M derived: sum of 2 quarters · filed 2020-10-29 | $7.30M derived: sum of 3 quarters · filed 2020-10-29 | |||
| 2019-06-30 | $2.15M 10-Q · filed 2020-10-29 | $4.17M derived: sum of 2 quarters · filed 2020-10-29 | ||||
| 2019-03-31 | $2.02M 10-Q · filed 2020-10-29 | |||||
| 2018-12-31 | $6.64M 10-K · filed 2021-02-25 | |||||
| 2018-09-30 | $1.14M 10-Q · filed 2019-11-13 | $3.41M derived: sum of 2 quarters · filed 2019-11-13 | $4.98M derived: sum of 3 quarters · filed 2019-11-13 | |||
| 2018-06-30 | $2.28M 10-Q · filed 2019-11-13 | $3.85M derived: sum of 2 quarters · filed 2019-11-13 | ||||
| 2018-03-31 | $1.57M 10-Q · filed 2019-11-13 | |||||
| 2017-12-31 | $6.34M 10-K · filed 2020-02-28 | |||||
| 2016-12-31 | $4.98M 10-K · filed 2019-02-26 | |||||
| 2015-12-31 | $2.89M 10-K · filed 2018-03-13 | |||||
| 2014-12-31 | $641.00K 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |